Candel Therapeutics, Inc. has announced a significant new sales agreement that will allow the company to sell up to $50 million in shares of its common stock. This move is part of the company's broader strategy to raise capital and support its operations in the competitive biological products sector.

On November 12, 2026, Candel Therapeutics entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC. Under this agreement, the company can sell its common stock through Jefferies acting as the sales agent. This agreement builds on a previous sales agreement established in 2025, which also had a maximum offering price of $50 million.

The ability to raise additional funds through this agreement is crucial for Candel Therapeutics as it continues to navigate the challenges of the biological products industry. The company has already sold approximately $50 million worth of shares under the previous agreement, demonstrating its proactive approach to securing necessary funding.

Background

Candel Therapeutics, Inc. is a publicly traded company listed on the Nasdaq under the ticker symbol CADL. The company specializes in the development of biological products, specifically those that do not involve diagnostic substances, as classified under SIC code 2836. Candel Therapeutics is incorporated in Delaware and is categorized as an emerging growth company.

What the Filing Says

The SEC filing states, "On November 12, 2026, Candel Therapeutics, Inc. entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to sell shares of the Company’s common stock...having an aggregate offering price of up to $50,000,000." The filing also notes that sales will be made through methods permitted for an "at the market offering" as defined by the Securities Act.

Impact

This new sales agreement may affect various stakeholders, including investors and competitors within the biological products sector. Investors may view this as a positive sign of Candel's commitment to growth and development. Competitors may need to adjust their strategies in response to Candel's capital-raising efforts.

What's Next

The filing does not specify what happens next, but it implies that Candel Therapeutics will begin selling shares under the new agreement as market conditions allow.